AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Emulsion de scott target9/8/2023 ![]() ![]() To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. In clinical studies, patients have occasionally experienced nausea during Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate therapy. The most common (>10%) adverse reactions are hypercalcemia, nausea and vomiting. Hypercalcemia may aggravate digitalis toxicity. Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg 2/dL 2. Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3 month study of solid dose formulation of Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate all cases resolved upon lowering the dose or discontinuing treatment. The long term effect of Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate on the progression of vascular or soft tissue calcification has not been determined. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. Decreasing or discontinuing Vitamin D therapy is recommended as well.Ĭhronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Mild hypercalcemia is usually controlled by reducing the Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate dose or temporarily discontinuing therapy. Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate therapy. More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Should hypercalcemia develop, reduce the Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia Therefore, early in the treatment phase during the dosage adjustment period, monitor serum Emulsion de Scott Sabor Cereza (Calcium Phosphate) levels twice weekly. Avoid the use of Emulsion de Scott Sabor Cereza (Calcium Phosphate) supplements, including Emulsion de Scott Sabor Cereza (Calcium Phosphate) based nonprescription antacids, concurrently with Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate.Īn overdose of Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate may lead to progressive hypercalcemia, which may require emergency measures. Patients with end stage renal disease may develop hypercalcemia when treated with Emulsion de Scott Sabor Cereza (Calcium Phosphate), including Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate. Hypercalcemia may aggravate digitalis toxicity. ![]() Severe hypercalcemia may require hemodialysis and discontinuation of Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate. Treat mild hypercalcemia by reducing or interrupting Emulsion de Scott Sabor Cereza acetate and Vitamin D. Capsule: 667 mg Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate capsule. (2)Ĭapsule: 667 mg Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate capsule. Most patients require 3 to 4 capsules with each meal. Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Starting dose is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. The recommended initial dose of Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate for the adult dialysis patient is 2 capsules with each meal. Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. Emulsion de Scott Sabor Cereza (Calcium Phosphate) acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). ![]()
0 Comments
Read More
Leave a Reply. |